To order this detailed 290+ page report, please visit this link

Key Inclusions
 A detailed review of the overall landscape of companies offering in silico drug discovery services for large molecules, including information on year of establishment, company size, location of headquarters, type of business model used (contract service providers (CROs), software / technology providers, consulting service providers and training service providers), number of drug discovery step(s) for which the company offers services involving the use of in silico approaches (target identification, target validation, hit generation, hit-to-lead and lead optimization), type of large molecules(s) handled (antibodies (monoclonal antibodies, bispecific antibodies, polyclonal antibodies, antibody drug conjugates (ADCs), antibody fragments, single domain antibodies, antisense antibodies and others), proteins (fusion proteins, protein fragments, enzymes and hormones), peptides, cell therapies, gene therapies, vectors and nucleic acids), type of in silico approach used (structure-based drug design (SBDD), fragment-based drug design (FBDD), target-based drug design (TBDD), ligand-based drug design (LBDD) and interface-based drug design (IBDD)), type of in silico service(s) offered (virtual screening, molecular docking, molecular modeling, scaffold hopping and 8+ services), and type of clientele served (pharmaceutical / biotechnology companies and academic / research institutes).
 Insights on contemporary market trends, depicted using four schematic representations, which include [A] a logo landscape of the industry players engaged in this domain, distributed based on the basis of location of their company size (small (1-50 employees), mid-sized (51-200 employees) and large (>200 employees)) and respective headquarters, [B] a tree map representation of in silico service providers, featuring a distribution of stakeholders on the basis of the company size and drug discovery steps, [C] a world map representation, highlighting the key hubs with respect to outsourcing activity within this domain, and [D] an insightful grid analysis, presenting the distribution of companies based on the type of large molecule, in silico approach used and type of clientele.
 Elaborate profiles of key industry players that offer a wide range of in silico drug discovery services, featuring a brief overview of the company (including details related to year of establishment, company size, location of headquarters and key members of the executive team), funding and investment information (if available), in silico-based service(s) portfolio) and an informed future outlook.
 A detailed peer group-based benchmarking analysis, comparing the involved players based on several relevant parameters, such as the experience of the company, number of drug discovery step(s), number of in silico service(s) offered, number of large molecule(s) for which the aforementioned services are offered and type of clientele.
 An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain on the basis of the strength of their respective service portfolios, taking into consideration the experience of a service provider, number of drug discovery services offered and number of large molecules, for which the aforementioned services are offered.
 A detailed analysis assessing the current opportunity within in silico drug discovery services market, comparing the number of pipeline products and current market size across different types of large molecules, and the availability and capabilities of affiliated in silico drug discovery service providers.
 A discussion on the various business strategies that can be adopted by in silico drug discovery service providers in order to maintain a competitive edge in this industry, based on the different types of large molecules handled and the technical expertise of service providers, in terms of capabilities across different steps of drug discovery.
 An insightful analysis highlighting the cost saving potential associated with the use of in silico approaches in the drug discovery process.
 A case study comparing the key challenges associated with the discovery and production of large molecules, affiliated product development timelines, and manufacturing protocols, with those of small molecule drugs.
 Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in providing in silico services for discovery of large molecule drugs.
 A discussion on the upcoming computational approaches (such as artificial intelligence and cloud computing) that are being adopted for drug discovery purposes and are likely to impact early stage research over the coming years.
 A case study highlighting several non-computational methods / technologies, which are considered to be of significant importance to the overall drug discovery process.


The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:

 Key Drug Discovery Steps
 Target Identification
 Target Validation
 Hit Generation
 Hit-to-Lead
 Lead Optimization

 Type of Large Molecule
 Antibodies
 Proteins
 Peptides
 Nucleic Acids
 Vectors

 Company Size
 Small
 Mid-sized
 Large

 Target therapeutic Area
 Autoimmune Disorders
 Blood Disorders
 Cardiovascular Disorders
 Gastrointestinal and Digestive Disorders
 Hormonal Disorders
 Human Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
 Infectious Diseases
 Metabolic Disorders
 Mental Disorders
 Musculoskeletal Disorders
 Neurological Disorders
 Oncological Disorders
 Respiratory Disorders
 Skin Disorders
 Urogenital Disorders
 Others

 Type of Sponsor
 Industry Players
 Non-Industry Players

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific

The report includes detailed transcripts of discussions held with the following experts:
 John L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
 Sven Benson (Founder, candidum)
 Mark Whittaker (Senior Vice President, Evotec)
 Edelmiro Moman (Scientific Consultant and Teacher, ProSciens)

To request sample pages, please visit this link

Key Questions Answered
 Who are the leading in silico service providers for discovery of different types of large molecule drugs?
 What are the key challenges associated with the discovery of large molecule drugs?
 What is the likely cost saving opportunity associated with the use of in silico tools?
 What are the key computational approaches being used by in silico service providers for drug discovery operations?
 What are the popular business strategies being used by in silico drug discovery service providers?
 How is the current and future market opportunity likely to be distributed across key market segments?

You may also be interested in the following titles:
4. DNA-Encoded Libraries: Platforms and Services Market
5. Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030
6. Companion Diagnostics Services Market, 2020-2030

Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]